抗肺線維症作用を有する可能性のある薬剤の包括的レビュー

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties.

抄録

肺線維症は、肺における瘢痕組織の蓄積を特徴とする慢性かつ進行性の肺疾患であり、肺機能の低下やQOLの低下をもたらす。ー特発性肺線維症（ーIPFはー肺線維症のー予後がー悪い。年である。ーIPFのー現在現在現在ー現在現在現在ー現在ー現在ー現在ー現在ー現在のー現在ー現在ー現在ー現在ー現在ーーーピルフェニドンとーニンテダニブ。ーIPFのーIPFのー肺線維症ーーーー本総説は、特発性肺線維症に対する現在および将来の薬物介入の最新の概要を提供し、潜在的な抗肺線維症薬の標的の可能性をまとめ、さらなる臨床的併用療法や新薬開発の理論的裏付けを提供することを目的とする。

Pulmonary fibrosis is a chronic and progressive lung disease characterized by the accumulation of scar tissue in the lungs, which leads to impaired lung function and reduced quality of life. The prognosis for idiopathic pulmonary fibrosis (IPF), which is the most common form of pulmonary fibrosis, is generally poor. The median survival for patients with IPF is estimated to be around 3-5 years from the time of diagnosis. Currently, there are two approved drugs (Pirfenidone and Nintedanib) for the treatment of IPF. However, Pirfenidone and Nintedanib are not able to reverse or cure pulmonary fibrosis. There is a need for new pharmacological interventions that can slow or halt disease progression and cure pulmonary fibrosis. This review aims to provide an updated overview of current and future drug interventions for idiopathic pulmonary fibrosis, and to summarize possible targets of potential anti-pulmonary fibrosis drugs, providing theoretical support for further clinical combination therapy or the development of new drugs.